Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04186806 · ClinicalTrials.gov registry record · NA
Evaluation of the Efficacy of 3M Dry Mouth Moisturizing Spray
A NA study of Xerostomia, sponsored by Solventum US.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT04186806: Completed NA study of Xerostomia, sponsored by Solventum US.
NCT04186806 is a NA study of Xerostomia that has completed, run by Solventum US. The registered enrollment target is 40 participants, below the 92-participant average among 13 other Xerostomia trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04186806, a NA study of Xerostomia, has completed, sponsored by Solventum US.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the clinical trial is to evaluate and validate the performance of the experimental mouth spray when used by persons with mild to severe dry mouth symptoms.
Primary Outcome
Primary endpoint will be paired-difference in Visual Analog Scale (VAS) between experimental and active control product. On the scale 0 represents normal and 10 represents worst imaginable dry mouth symptoms.
Conditions Studied
Interventions
- DEVICE 3M Dry Mouth Moisturizing Spray to Biotene Moisturizing Mouth Spray
- DEVICE Biotene Moisturizing Mouth Spray to 3M Dry Mouth Moisturizing Spray
Study Locations (1)
California
- Loma Linda University, School of Dentistry - Loma Linda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2019-11-02 |
| Est. Completion | 2019-12-13 |
| Phase | NA |
What the finished NCT04186806 record still lists
NCT04186806 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 92-participant average among 13 other Xerostomia trials with a reported enrollment target (57% lower).
The record links to 1 condition, with Xerostomia appearing as the primary indexed condition, and to 2 interventions - of which 3M Dry Mouth Moisturizing Spray to Biotene Moisturizing Mouth Spray is the first listed.
NCT04186806 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04186806 about?
NCT04186806 is a clinical study titled "Evaluation of the Efficacy of 3M Dry Mouth Moisturizing Spray". The purpose of the clinical trial is to evaluate and validate the performance of the experimental mouth spray when used by persons with mild to severe dry mouth symptoms.
What is the current status of trial NCT04186806?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2019-11-02. Estimated completion is 2019-12-13.
What conditions does trial NCT04186806 study?
This clinical trial studies the following conditions: Xerostomia.
What interventions are being tested in trial NCT04186806?
The interventions under investigation include: 3M Dry Mouth Moisturizing Spray to Biotene Moisturizing Mouth Spray (DEVICE), Biotene Moisturizing Mouth Spray to 3M Dry Mouth Moisturizing Spray (DEVICE).
Who is sponsoring clinical trial NCT04186806?
This trial is sponsored by Solventum US, which has 41 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04186806 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Xerostomia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04186806's enrollment target sits among peer trials
40 8th of 13 higher than 5 of 13 other Xerostomia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Xerostomia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Whitening Agent With Emulsion Gel in Saliva and Halitosis
ACTIVE NOT RECRUITING · NA
-
SaliPen Human Factors Study for OTC Labeling
COMPLETED · NA
-
Consumer Perception of an Experimental Mouthwash After a Single Use in Dry Mouth Subjects
COMPLETED · NA
-
Potential of an Experimental Mouthwash Formulation to Reduce Dry Mouth Symptoms
COMPLETED · NA
-
d-Limonene +Radiation +PlatinumBasedChemo for Xerostomia Prevention in LocallyAdvanced HNSCC
RECRUITING · Phase 1
-
Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI